Helping your patients make the right choice

With recent research showing that almost a third of Irish women aged 17-45 have had sex in the past where contraception has failed, there is a clear need to offer the most effective contraceptive methods.1 In an on-line survey of 1,014 Irish females aged 17 to 45 years of age where they were asked about contraception, almost three quarters (73%) of those who have experienced a contraceptive failure in the past claim that they were using a condom / male sheath when the contraception failed.1 Whilst just over a third of women aged 17-45 have had sex in the past where the contraception failed, and this resulted in a pregnancy. 1Long-acting methods can be the most effective form of contraception because they do not rely on user compliance.2


Here you will find resources to guide conversations with your patients, helping to identify which is the most suitable contraception for them.

Use the Range of contraception leaflet with your patients to discuss the different options available and to help them make an informed decision on which contraception is best for them.


Pill compliance is a common struggle for women1

For every 100 women that choose to take the pill this year, nine could become pregnant due to missed-pill moments.2 Long-acting methods such as intrauterine systems (IUS) offer birth control with the highest available efficacy and are one of the most effective contraceptive methods because their effectiveness is independent of user compliance.3


Pill compliance

Choose an IUS that best meets her needs

13.5 mg intrauterine delivery system (levonorgestrel)
19.5 mg intrauterine delivery system (levonorgestrel)
52 mg intrauterine delivery system (levonorgestrel)
Indication Contraception for up to 3 years Contraception for up to 5 years Contraception for up to 8 years.
Treatment of idiopathic menorrhagia for up to 5 years. If symptoms have not returned after 5 years of use, continued use of the system may be considered.  Mirena should be removed or replaced after 8 years at the latest.
Protection from endometrial hyperplasia during estrogen replacement therapy for up to 5 years
Pearl Index (efficacy) Year 1:0.41
3-years: 0:33
Year 1: 0.41
3-years: 0.33
Year 1: 0.2
Years 5: 0.144
Years 6-8: 0.28
Contraceptive failure rate 0.4% at 1 year
0.9% over 3 years
0.2% at 1 year
1.4% over 5 years
Year 1: 0.2%
Years 1 to 5: 0.7%
Years 6 to 8: 0.68
Total levonorgestrel (LNG) content (mg) 13.5 19.5 52
Average in vivo LNG release rate over the first year of use 8 μg/24 hours 12.6 μg/24 hours2 20 μg/24 hours
% of women experiencing amenorrhoea and infrequent bleeding at 1 year post insertion Amenorrhoea: 6%
infrequent bleeding: 20%
Amenorrhoea: 12%
infrequent bleeding: 26%
Amenorrhoea: 16%
infrequent bleeding: 57%
T-frame size (mm) 28 × 30 28 × 30 32 × 324
Placement tube diameter size (mm) 3.8 3.8 4.4
Colour of monofilament threads Brown Blue Brown
Differentiator in imaging techniques:silver ring Improved visibility on ultrasound Improved visibility on ultrasound -

If you are an inserter of IUS, visit Inserter resources which covers all the practical aspects of the IUS insertion process, including preparation and loading advice.

Reporting adverse events and quality complaints

If you want to report a side effect or quality complaint, please contact your health care professional (e.g. physician or pharmacist) or The Health Products Regulatory Authority, Reports can also be reported directly to Bayer through this link or by emailing directly on